- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run | 282 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways.The... ► Artikel lesen | |
| 16.12.25 | EXOZYMES INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.12.25 | eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion | 338 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / December 11, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.11.25 | eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today | 348 | ACCESS Newswire | Management to host Q3 2025 update at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced... ► Artikel lesen | |
| 13.11.25 | eXoZymes appoints co-founder as CSO, adds new chief of staff | 5 | Investing.com | ||
| 13.11.25 | eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff | 337 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / November 13, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 13.11.25 | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | EXOZYMES INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.11.25 | eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST | 325 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / November 10, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 30.10.25 | CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference | 335 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.10.25 | CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference | 333 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 29, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 23.10.25 | CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference | 289 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 03.10.25 | EXOZYMES INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.09.25 | Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees | 354 | ACCESS Newswire | LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 12.08.25 | eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today | 461 | ACCESS Newswire | Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered... ► Artikel lesen | |
| 12.08.25 | EXOZYMES INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 08.08.25 | eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST | 397 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals... ► Artikel lesen | |
| 29.07.25 | eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity | 510 | ACCESS Newswire | Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.NCT project went from concept to... ► Artikel lesen | |
| 22.07.25 | eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months | 523 | ACCESS Newswire | N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial... ► Artikel lesen | |
| 26.06.25 | eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing | 440 | ACCESS Newswire | MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 309,11 | 0,00 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| COGENT BIOSCIENCES | 37,960 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,74 | +0,23 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,650 | -0,27 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,060 | -2,77 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ARCELLX | 69,47 | 0,00 % | Arcellx präsentiert Daten zu Anito-Cel auf den Tandem Meetings 2026 | ||
| ARCUTIS BIOTHERAPEUTICS | 25,570 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis | 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 75,62 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 65,93 | +2,15 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ERASCA | 10,610 | 0,00 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| RECURSION PHARMACEUTICALS | 4,175 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| LENZ THERAPEUTICS | 16,300 | 0,00 % | New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug | ||
| ALUMIS | 26,420 | +7,79 % | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| VERA THERAPEUTICS | 45,300 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen |
EXOZYMES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 10,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.